{Reference Type}: Journal Article
{Title}: Monkeypox: From Emerging Trends to Therapeutic Concerns.
{Author}: Piparva KG;Fichadiya N;Joshi T;Malek S;
{Journal}: Cureus
{Volume}: 16
{Issue}: 4
{Year}: 2024 Apr
暂无{DOI}: 10.7759/cureus.58866
{Abstract}: Monkeypox is a zoonotic viral disease. Monkeypox was first reported in humans about 54 years ago. Prior to the global outbreak, monkeypox was endemic to the rainforests of central and western African countries. In the last three years, increasing numbers of human monkeypox have been reported from various countries. Responding to the severity, monkeypox was declared a Public Health Emergency of International Concern by the World Health Organization. In the absence of approved drugs or clinical studies, repurposed drugs and therapeutic medical countermeasures effective against other orthopoxviruses have been utilized to treat severe human monkeypox cases. Currently, clinical trials are underway exploring the potential therapeutic effectiveness of tecovirimate in human monkeypox cases. Monoclonal antibodies, IFN-β, resveratrol, and 15 triple-targeting FDA-approved drugs represent potential new drug targets for human monkeypox, necessitating further research.